COMPANY

Company History

Curacle, a Biopharma with Innovative Technology,
Global Competitiveness, and Sustainable Growth Potential

  • 2022

  • 07 CU01(diabetic nephropathy), Phase 2a IND application approved

    06 Computer-Aided drug design

    CU06, Finalized CU06 Phase1 CSR

    04 Relocated research center and welcomed Seocho Headquarters phase

    01 Established 2nd bio research center

  • 2021

  • 10 New CEO Appointed

    CU06, Out-licensed to ophthalmology company Thea for 200 Billion USD

    09 CU01 (Diabetic nephropathy), Submitted Phase 3 IND

    07 Listed on KOSDAQ (365270)

    03 Passed the technical evaluation for Special Technology Assessment Track listing(grade: AA, A)

    CU01 (Diabetic nephropathy), Confirmed safety and efficacy in Phase 2a clinical trial

    02 CU06 (Diabetic Macular Edema), Phase 1 IND approved by FDA (NCT04795037)

    01 Signed MOU with College of Pharmacy & Institute of Pharmaceutical Science and Technology Research, Korea University

  • 2020

  • 12 Signed research agreement with Severance Hospital

    11 CU06 (Vessel Protector & Zipper) U.S. Clinical DP Production Completed (cGMP)

    Signed research agreement with Yonsei University and opened industry-academic cooperation biolab

    Inno-Biz certification (certification number: 200605–01197)

    10 Introduction and Transition of Electronic Securities System

    Funding raised (US$ 4 million)

    08 Awarded ‘Bio-Tech Science Innovation Award’ from “2020 6th Korea Leading Enterprise Awards”

    CU01 (Diabetic Nephropathy), Completed Test Subject Recruitment for Clinical 2a Phase

    CU03 (Wet AMD), Completed Clinical 2a Phase tolerability Assessment, Recruited additional 60 subjects

    Appointment of stock transfer agent (Korea Securities Depository)

    06 Signed research agreement for formulation development with LS Pharma

    04 Startups Research Infra Utilization (Research Focused) Grant awarded by the Ministry of SMEs

    CU06, Pharmaceutical Industry Global Advancement Supporting Grant awarded by the Ministry of Health and Welfare

    03 CU06, signed CMO service contract with Yuhan Chemical (South Korea) for cGMP DS production of FDA Phase 1 study

    01 Established Bio & Analytical Laboratory at Pangyo 2nd Techno Valley

  • 2019

  • 12 CU03 (Wet AMD), Phase 2a IND approved by Ministry of Food and Drug Safety(MFDS)

    11 Signed Consultation contract with BL&H (USA) for global BD

    Funding raised (US$ 7.1 million)

    10 Relocated headquarters to Pangyo 2nd Techno Valley

    CU06, signed CMO service contract with Patheon (USA) for formulation study & cGMP DP production

    07 Samsung Securities selected as underwriter for IPO

    06 CU06, Signed CRO service contract with Covance (UK) for global GLP nonclinical study

    05 CU01 (Diabetic Nephropathy), Phase 2a IND approved by Ministry of Food and Drug Safety(MFDS)

    04 CU06, Signed Technology transfer agreement of Vessel Protector & Zipper from Yonsei University

    01 Relocated R&D center (from Daegu Gyeongbuk Medical Innovation Foundation (DGMIF) to Korea Research Institute of Chemical Technology (KRICT), Daejeon)

  • 2018

  • 12 Nominated as a membership business of the Korea Research Institute of Chemical Technology (KRICT)

    11 Funding raised (US$ 9.0 million)

    10 Relocated headquarters (Woorim W-city at Pangyo)

    03 CU05 (Lung Cancer), Grant awarded by the Ministry of Science and ICT for the biomedical technology development business project

    01 CU02 (NASH & Obesity), Grant awarded by the Ministry of Science and ICT for the biomedical technology development business

  • 2017

  • 10 CU04 (immunotherapy), Grant awarded by Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF) New Drug Development Center for optimization support

    08 CU02 (NASH & Obesity), Signed Technology transfer agreement from Gwangju Institute of Science and Technology (GIST), Korea Advanced Institute of Science and Technology (KAIST) & Kyungpook National University (KNU)

    06 CU01, Grant awarded from the Ministry of Trade, Industry and Energy

    05 CU01 Signed research contract with Mcnulty for formulation development

    04 CU05, Signed research agreement with College of Pharmacy, Gachon University

    03 CU03 (Macular Degeneration), Signed technology transfer agreement from Korea Institute of Oriental Medicine (KIOM)

    02 CU01 (Renal Fibrosis), Signed technology transfer agreement from Kyungpook National University

    CU05 (Lung Cancer), Signed technology transfer agreement from Yonsei University

    01 Established R&D center at Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF) certified as affiliated research institute

  • 2016

  • 11 Registered as a venture business (No. 20160300500)

    Relocated headquarters (Innovalley at Pangyo)

    10 Funding raised (US$ 1.5 million)

    05 Established Curacle Co., Ltd. (Gangnam, Seoul)